Company intelligence / Profile preview

Alya

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Alya Therapeutics is an early-stage biotechnology company focused on the discovery and development of novel small molecule inhibitors for the treatment of cancer. The company's primary focus is on targeting the deubiquitinating enzyme USP7, which plays a critical role in regulating the stability of key tumor suppressors and oncogenes. By inhibiting USP7, Alya aims to restore natural tumor-suppressive pathways and induce apoptosis in cancer cells. The company is currently advancing its lead programs through pre-clinical development, targeting both solid tumors and hematological malignancies.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Alya.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alya.

Explore the full profile